Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous ultra-low-dose rituximab retreatment in rheumatoid arthritis
NL-OMON52719Phase 4Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of rituximab, sponsored by Sint Maartenskliniek. Started Apr 2022; status: completed.
02
Drugs
rituximab
Beyond the preview
Go deeper on NL-OMON52719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52719.